Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2303 vs Rituximab in Aggressive CD20+ NHL
NCT03456466Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in non-Hodgkin lymphoma (NHL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03456466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456466.